BillionToOne (NASDAQ:BLLN) shares drop 39% after maintained guidance signals weaker second half

BillionToOne, Inc. heads into the final trading stretch of the year with investors juggling two competing truths: the diagnostics newcomer has posted eye-catching growth and profitability metrics for a just-public company, but the stock remains volatile after a headline-grabbing debut and a sharp December pullback.

BillionToOne, Inc. heads into the weekend with fresh attention after a late-week rebound in a holiday-thinned tape, while Wall Street’s early coverage continues to frame the newly public molecular diagnostics company as a high-growth story with meaningful upside—paired with the kind of volatility that tends to follow recent IPOs.